Evidence map›Paper›PMID 25066886›Full record

SynthesisJournal of clinical virology : the official publication of the Pan American Society for Clinical Virology2014

The relevance of respiratory viral infections in the exacerbations of chronic obstructive pulmonary disease—a systematic review.

W A R Zwaans, P Mallia, M E C van Winden, G G U Rohde

Registry-linked trialOpen access · greenAbstract readSystematic Review
In one paragraph

Synthesis in Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03851991 (A 52-week Multicenter, Randomized, Double-blind, Placebo-controlled, Prospective Study to Evaluate the Efficacy and Safety of Arbidol in Reducing the Frequency of AECOPD.), which is not on this map. Cited by 72 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 3 pooled it
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03851991 phase4completednot on this mapstarted 2019, after this paper: background citation

A 52-week Multicenter, Randomized, Double-blind, Placebo-controlled, Prospective Study to Evaluate the Efficacy and Safety of Arbidol in Reducing the Frequency of AECOPD.

TypeinterventionalSponsorShengjing HospitalRan2019 to 2024Enrolled351ConditionsCOPD PatientsArmsArbidol, Placebos
3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 3 syntheses or guidelines pooled it, 129 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Journal of preventive medicine and hygiene · 2024
    Article
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

W A R ZwaansDepartment of Respiratory Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands.
P MalliaDepartment of Respiratory Medicine, Imperial College London, London, United Kingdom.
M E C van WindenDepartment of Respiratory Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands.
G G U RohdeDepartment of Respiratory Medicine, Maastricht University Medical Centre, Maastricht, The Netherlands. Electronic address: g.rohde@mumc.nl.
Maastricht University Medical Centre · NLImperial College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite the increasing knowledge on the role of viruses in exacerbations of COPD (AECOPD), it is less clear which viruses are involved and to what extent they contribute to exacerbations. This review aims to systematically combine and evaluate the available literature of the prevalence of respiratory viruses in patients with AECOPD, detected by PCR.

methodsAn electronic search strategy was performed on PubMed and Embase and reference lists were screened for eligible studies. Cross-sectional, prospective studies and case-control studies were included. The primary outcome measure was the prevalence of respiratory viruses (adenovirus, bocavirus, coronavirus, EBV, hMPV, influenza, parainfluenza, rhino-/enterovirus, RSV) in respiratory secretions of patients during an AECOPD. Secondary outcomes were the odds of the presence of the viruses in different respiratory secretions and the odds of the presence of viruses in upper and lower respiratory tract (URT/LRT) samples.

resultsNineteen studies with 1728 patients were included. Rhino-/enteroviruses (16.39%), RSV (9.90%) and influenza (7.83%) were the most prevalent viruses detected with lower detection rates of coronaviruses (4.08%) and parainfluenza (3.35%). Adenovirus (2.07%), hMPV (2.78%) and bocaviruses (0.56%) appear to be rare causative agents of AECOPD. Definitive conclusions regarding the role of EBV cannot be made. Seven of the eight analyzed viruses had a higher prevalence in LRT samples. Coronaviruses were detected more frequently in the URT.

conclusionsRespiratory viruses are frequently detected in both URT and LRT samples in AECOPD with rhino-/enteroviruses, RSV and influenza viruses the most prevalent viruses. Detection rates vary between the two sites for different viruses.

Indexed as

Bodily SecretionsHumansPolymerase Chain ReactionPrevalencePulmonary Disease, Chronic ObstructiveRespiratory SystemRespiratory Tract InfectionsVirus DiseasesVirusesExacerbationPolymerase chain reactionPulmonary disease, chronic obstructiveSystematic reviewViruses

Identifiers

PMID25066886
PMCPMC7106508
OpenAlexW2105041666

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.